A retrospective real-world study of pyrotinib in HER-2 positive advanced breast cancer

Pyrotinib maleate, a novel oral tyrosine kinase inhibitor, irreversibly binds to ATP binding sites in HER1, HER2 and HER4 intracellular segments, blocking activation of key signaling pathways and inhibiting tumor cell growth. The antitumor activity of pyrotinib has previously been demonstrated in clinical trials and has been recommended for second-line treatment of advanced HER2-positive breast cancer at Class 2A evidence level by the Chinese Society of Clinical Oncology. However, the strict inclusion criteria of clinical trials may not reflect the safety and efficacy of pyrotinib in a real-world clinical setting. This research article from Cancer Management and Research aims to address this.